Richard Jadick, DO
Urology · Lagrange, GANPI 1083837975
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,334 of the $47,045 with a category attached, or 60.2%. Teleflex LLC accounts for 69.5% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2021 at $24,208 and has fallen 89.6% since, to $2,519 in 2025. Among urology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $135.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$33K
- Coloplast$3K
- Axonics, Inc.$3K
- Intuitive Surgical$2K
- Procept Biorobotics Corporation$2K
- Neotract Inc.$2K
- plus $3K from 30 others
What the payments were for
- Consulting fees$5851%
- Speaking & faculty fees$28,33460%
- Travel & lodging$9,57420%
- Food & beverage$8,34718%
- Education$2050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 51 | $32,711 |
| Coloplast | 76 | $3,063 |
| Axonics, Inc. | 67 | $2,839 |
| Intuitive Surgical | 10 | $2,045 |
| Procept Biorobotics Corporation | 18 | $1,934 |
| Neotract Inc. | 13 | $1,584 |
| Boston Scientific | 28 | $1,104 |
| Sumitomo Pharma America, Inc. | 14 | $277 |
| Astellas Pharma US Inc | 9 | $233 |
| Medtronic(2 entities) | 8 | $125 |
| Endo Pharmaceuticals Inc. | 6 | $122 |
| Palette Life Sciences, Inc. | 1 | $98 |
| Urovant Sciences Inc | 5 | $83 |
| Johnson & Johnson | 2 | $72 |
| Calyxo, Inc. | 2 | $59 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $57 |
| Myovant Sciences Inc. | 3 | $51 |
| 180 Medical, Inc. | 2 | $51 |
| Laborie Medical Technologies Corp. | 3 | $48 |
| AbbVie | 2 | $43 |
| Enterra Medical, Inc. | 1 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $42 |
| Rochester Medical Corporation | 2 | $34 |
| Bayer | 2 | $34 |
| Tolmar, Inc. | 1 | $32 |
| Olympus America Inc. | 2 | $32 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Blue Earth Diagnostics | 1 | $29 |
| Angiodynamics, Inc. | 2 | $27 |
| Endo USA, Inc. | 1 | $26 |
| Agiliti Surgical, Inc. | 1 | $22 |
| Merck | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Telix Pharmaceuticals | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 5 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$30,390
- UroLift$2,803
- Da Vinci Surgical System$1,844
- TITAN$1,714
- AQUABEAM SYSTEM$1,489
- Axonics r-SNM System$842
- Bulkamid$730
- Axonics$569
- AquaBeam Robotic System$152
- LITHOCLAST$133
- AMS 700$106
How this compares
$47,045 in reported general payments places this provider in the 95th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 56 | $42,721 |
| MyrbetriqMirabegron | 23 | $25,120 |
| Testosterone Cypionate | 93 | $4,847 |
| Tolterodine Tartrate ErTolterodine Tartrate | 46 | $4,615 |
| Tamsulosin Hcl | 375 | $3,954 |
| Oxybutynin Chloride ErOxybutynin Chloride | 235 | $3,900 |
| Ciprofloxacin Hcl | 268 | $1,898 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 38 | $1,537 |
| Desmopressin Acetate | 19 | $1,389 |
| Estradiol | 12 | $1,203 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $856 |
| Finasteride | 63 | $771 |
| Methylprednisolone | 66 | $425 |
| Solifenacin Succinate | 14 | $369 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 117 | $344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $277 | $42,72156 claims |
| Astellas Pharma US IncMyrbetriq | $233 | $25,12023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 369 urology providers in Georgia.
Other urology in Lagrange
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
- James BennettAtlanta$93K
- Anthony BarnesAtlanta$89K
- Scott MillerRoswell$85K
- Matthew SandAtlanta$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.